3:02 PM
 | 
Nov 10, 2017
 |  BC Extra  |  Company News

Omeros soars on single Phase III plan for OMS721

Omeros Corp. (NASDAQ:OMER) soared $4.08 (29%) to $18.17 Friday after announcing late Thursday that FDA will accept a single Phase III trial with a primary endpoint of proteinuria reduction to support approval of OMS721 to treat IgA nephropathy. Omeros plans to start the trial this year.

The company said there are no approved...

Read the full 248 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >